首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

2008070

鈣離子通道阻斷劑市場：依藥物類別、適應症、通路和地區分類。

Calcium Channel Blocker Drugs Market, By Drug Class, By Disease Indication, By Distribution Channel, By Geography

出版日期: 2026年03月20日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，鈣離子通道阻斷劑市場規模將達到174.606億美元，2033年將達到248.574億美元。預計從2026年到2033年，其複合年成長率將達到5.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	174.606億美元
業績數據週期：	2020-2024	預測期：	2026-2033
2026-2033年預測期間的複合年成長率：	5.20%	2033年市場規模預測：	248.574億美元

鈣離子通道阻斷劑是一類用於治療高血壓、心律不整（心率不規則）和心絞痛的藥物。它們透過阻斷部分鈣離子進入心臟和動脈發揮作用。鈣離子通道阻斷劑有多種劑型，從速溶片到緩釋膠囊。劑量取決於患者的整體健康狀況和病歷。

此外，慢性腎臟病是指腎功能在數年內逐漸衰退的一種疾病。隨著腎衰竭的進展和器官功能的嚴重受損，體內會迅速積聚危險水平的代謝廢物和體液。治療的目標是阻止或延緩疾病的進展，這通常是透過控制病因來實現的。鈣離子通道阻斷劑是一種用於治療慢性腎臟病或其病因的藥物。

市場動態

預計在預測期內，心血管疾病、肥胖和不健康生活方式的日益普遍將推動市場成長。

例如，根據世界衛生組織 (WHO) 2022 年的報告，2019 年估計有 1,790 萬人死於心血管疾病，其中 85% 的死亡是由心肌梗塞或中風引起的。

由於新核准和核准的鈣離子通道阻斷劑的增加，預計市場在預測期內將顯著成長。

例如，2022 年 6 月，製藥公司 CMP Pharma, Inc. 獲得了美國食品藥物管理局 ( 食品藥物管理局核准鈣離子通道阻斷劑患者的高血壓。

本次調查的主要特點

本報告對全球鈣離子通道阻斷劑市場進行了詳細分析，預測期（2026-2033 年）的市場規模和複合年成長率（%）為 2025 年為基準年。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球鈣離子通道阻斷劑市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務績效和策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球鈣離子通道阻斷劑市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
相關人員可以透過利用全球鈣離子通道阻斷劑市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
南非
中非
北非

第8章競爭情勢

衝突簡介
- Bausch Health
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd,
- Novartis AG
- Zydus Cadila
- Pfizer Inc,

第9章

參考
調查方法

簡介目錄

Product Code: CMI5153

Calcium Channel Blocker Drugs Market is estimated to be valued at USD 17,460.6 Mn in 2026 and is expected to reach USD 24,857.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 17,460.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.20%	2033 Value Projection:	USD 24,857.4 Mn

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ's function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study

This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Market Segmentation

Global Calcium Channel Blocker Drugs Market, By Drug Class
- Benzothizepine
- Dihydropyridine
- Phenylalkylamine
Global Calcium channel blocker drugs market, By Disease Indication
- Hypertension
- Chest Pain
- Arrhythmias
- Others (Blood vessel conditions, Coronary Artery Disease etc.)
Global Calcium Channel Blocker Drugs Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Calcium Channel Blocker Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Bausch Health
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc.
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Zydus Cadila
- Pfizer Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Benzothizepine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Dihydropyridine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Phenylalkylamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Arrhythmias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Others (Blood vessel conditions, coronary artery disease etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Calcium Channel Blocker Drugs Market, By Region, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
North America
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Region/Country, 2026 - 2033, (USD Mn)
South Africa
Central Africa
North Africa